NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

M7824 in Subjects With HPV Associated Malignancies

Phase 2

Completed

Conditions: Human Papilloma Virus
Cervical Cancer
Anal Cancer
Oropharyngeal Cancer
Vaginal or Penile Cancer

Interventions: Drug: M7824

First Posted Date: 2018-02-09

Last Posted Date: 2023-03-28

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 57

Registration Number: NCT03427411

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

Phase 2

Recruiting

Conditions: Non-Small Cell Lung Cancer
Breast Cancer
Ovarian Cancer
Gastrointestinal/Genitourinary Cancers
Endocrine Tumors
Neuroendocrine Tumors
Multiple Myeloma

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Aldesleukin
Biological: Individual Patient TCR-Transduced PBL
Drug: Pembrolizumab (KEYTRUDA(R))

First Posted Date: 2018-01-29

Last Posted Date: 2025-06-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 270

Registration Number: NCT03412877

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Generation of Cancer Antigen-Specific T-cells From Human Induced Pluripotent Stem Cells (iPSC) for Research and Potential FutureTherapy

Terminated

Conditions: Melanoma
Lung Cancer
Gastrointestinal Cancers
Breast Cancer
Pancreatic Cancer

First Posted Date: 2018-01-23

Last Posted Date: 2021-11-10

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 98

Registration Number: NCT03407040

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Effect of Ultra Processed Versus Unprocessed Diets on Energy Intake

Not Applicable

Completed

Conditions: Healthy Diet

Interventions: Dietary Supplement: Ultra-processed diet
Dietary Supplement: Unprocessed diet

First Posted Date: 2018-01-23

Last Posted Date: 2021-06-29

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 20

Registration Number: NCT03407053

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Broccoli Sprout/Broccoli Seed Extract Supplement in Decreasing Toxicity in Heavy Smokers

Early Phase 1

Completed

Conditions: Cigarette Smoking-Related Carcinoma
Tobacco-Related Carcinoma

Interventions: Drug: Broccoli Sprout/Broccoli Seed Extract Supplement
Other: Laboratory Biomarker Analysis
Other: Questionnaire Administration

First Posted Date: 2018-01-18

Last Posted Date: 2023-06-28

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 49

Registration Number: NCT03402230

Locations: 🇺🇸
Banner University Medical Center - Tucson, Tucson, Arizona, United States
🇺🇸
University of Arizona Cancer Center - Prevention Research Clinic, Tucson, Arizona, United States

Methyldopa for Reduction of DQ8 Antigen Presentation in At-Risk Subjects for Type 1 Diabetes

Phase 2

Withdrawn

Conditions: Type1 Diabetes Mellitus

Interventions: Drug: Placebo
Drug: Methyldopa

First Posted Date: 2018-01-11

Last Posted Date: 2020-06-30

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Registration Number: NCT03396484

ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma

Phase 2

Completed

Conditions: Hormone Receptor Positive, HER2 Negative Breast Cancer
Endometrial Cancer
Triple Negative Breast Cancer

Interventions: Drug: ONC201

First Posted Date: 2018-01-09

Last Posted Date: 2022-08-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT03394027

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy

Phase 1

Active, not recruiting

Conditions: Prostate Cancer
Cancer Of Prostate
Prostate Neoplasms
Prostatic Cancer
Neoplasms of Prostate

Interventions: Radiation: Prostate bed with integrated boost
Radiation: Prostate bed irradiation only
Diagnostic Test: Whole Body Bone Scan
Diagnostic Test: 18F-NaF PET Imaging
Diagnostic Test: CT
Diagnostic Test: mpMRI
Drug: ADT

First Posted Date: 2018-01-03

Last Posted Date: 2025-05-08

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT03388619

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers

Phase 1

Completed

Conditions: Treatment-Refractory Cancers
Metastatic Solid Tumors

Interventions: Drug: rhIL-15
Drug: Ipilimumab
Drug: Nivolumab

First Posted Date: 2018-01-03

Last Posted Date: 2025-05-22

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 31

Registration Number: NCT03388632

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced Cancer

Phase 1

Completed

Conditions: Prostate Cancer
Breast Cancer
Lung Cancer
Neoplasms
Colon Cancer

Interventions: Biological: ETBX-051; adenoviral brachyury vaccine
Biological: ETBX-061; adenoviral Mucin-1 (MUC1) vaccine
Biological: ETBX-011; adenoviral Carcinoembryonic antigen (CEA) vaccine

First Posted Date: 2017-12-27

Last Posted Date: 2020-09-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 11

Registration Number: NCT03384316

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy